The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Drug Discovery Targeting Bromodomain-Containing Protein 4
Open accessAbstract
BRD4, the most extensively studied member of the BET family, is an epigenetic regulator that localizes to DNA via binding to acetylated histones and controls the expression of therapeutically important gene regulatory networks through the recruitment of transcription factors to form mediator complexes, phosphorylating RNA polymerase II, and by its intrinsic histone acetyltransferase activity. Disrupting the protein-protein interactions between BRD4 and acetyl-lysine has been shown to effectively block cell proliferation in cancer, cytokine production in acute inflammation, and so forth. To date, significant efforts have been devoted to the development of BRD4 inhibitors, and consequently, a dozen have progressed to human clinical trials. Herein, we summarize the advances in drug discovery and development of BRD4 inhibitors by focusing on their chemotypes, in vitro and in vivo activity, selectivity, relevant mechanisms of action, and therapeutic potential. Opportunities and challenges to achieve selective and efficacious BRD4 inhibitors as a viable therapeutic strategy for human diseases are also highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
The Role of Chromatin during Transcription
Li, B., Carey, M., & Workman, J. L. (2007) · Cell · doi:10.1016/j.cell.2007.01.015 · Cited by 3,533
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Structure and ligand of a histone acetyltransferase bromodomain
Dhalluin, C., Carlson, J. E., Zeng, L., He, C., Aggarwal, A. K., Zhou, M.-M., & Zhou, M.-M. (1999) · Nature · doi:10.1038/20974 · Cited by 1,732
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J.-P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Müller, S., Pawson, T., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.013 · Cited by 1,694
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
Jang, M. K., Mochizuki, K., Zhou, M., Jeong, H.-S., Brady, J. N., & Ozato, K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.027 · Cited by 1,291
Targeting bromodomains: epigenetic readers of lysine acetylation
Filippakopoulos, P., & Knapp, S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4286 · Cited by 1,243
Acetylation: a regulatory modification to rival phosphorylation?
Kouzarides, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.6.1176 · Cited by 1,160
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
Archin, N. M., Liberty, A. L., Kashuba, A. D., Choudhary, S. K., Kuruc, J. D., Crooks, A. M., Parker, D. C., Anderson, E. M., Kearney, M. F., Strain, M. C., et al. (2012) · Nature · doi:10.1038/nature11286 · Cited by 1,139
Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4
Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,138
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L., & Sims, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108190108 · Cited by 1,110
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., Escara-Wilke, J., Wilder-Romans, K., Dhanireddy, S., Engelke, C., et al. (2014) · Nature · doi:10.1038/nature13229 · Cited by 927
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 834
Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF‐κB
Chen, L., Mu, Y., & Greene, W. C. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf660 · Cited by 827
Bromodomain: an acetyl‐lysine binding domain
Zeng, L., & Zhou, M.-M. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03309-9 · Cited by 746
BET domain co-regulators in obesity, inflammation and cancer
Belkina, A. C., & Denis, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3256 · Cited by 711
The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation
Wu, S.-Y., & Chiang, C.-M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r700001200 · Cited by 679
Small‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674
The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis
Dey, A., Chitsaz, F., Abbasi, A., Misteli, T., & Ozato, K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1433065100 · Cited by 669
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chanthery, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0418 · Cited by 637
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632
Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelA
Huang, B., Yang, X.-D., Zhou, M.-M., Ozato, K., & Chen, L.-F. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01365-08 · Cited by 579
RNA Polymerase II Elongation Control
Zhou, Q., Li, T., & Price, D. H. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052610-095910 · Cited by 571
BET inhibitor resistance emerges from leukaemia stem cells
Fong, C. Y., Gilan, O., Lam, E. Y. N., Rubin, A. F., Ftouni, S., Tyler, D., Stanley, K., Sinha, D., Yeh, P., Morison, J., et al. (2015) · Nature · doi:10.1038/nature14888 · Cited by 545
Rahman, S., Sowa, M. E., Ottinger, M., Smith, J. A., Shi, Y., Harper, J. W., & Howley, P. M. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01341-10 · Cited by 532
Identification of multiple cyclin subunits of human P-TEFb
Peng, J., Zhu, Y., Milton, J. T., & Price, D. H. (1998) · Genes & Development · doi:10.1101/gad.12.5.755 · Cited by 519
BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.
French, C. A., Miyoshi, I., Kubonishi, I., Grier, H. E., Pérez‐Atayde, A. R., & Fletcher, J. A. (2003) · PubMed · Cited by 501
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Rathert, P., Roth, M., Neumann, T., Muerdter, F., Roe, J.-S., Muhar, M., Deswal, S., Cerny-Reiterer, S., Peter, B., Jude, J., et al. (2015) · Nature · doi:10.1038/nature14898 · Cited by 499
Shi, J., Wang, Y., Zeng, L., Wu, Y., Deng, J., Zhang, Q., Lin, Y., Li, J., Kang, T., Tao, M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.028 · Cited by 477
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
Picaud, S., Wells, C., Felletar, I., Brotherton, D., Martin, S., Savitsky, P., Diez-Dacal, B., Philpott, M., Bountra, C., Lingard, H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310658110 · Cited by 468
Amorim, S., Stathis, A., Gleeson, M., Iyengar, S., Magarotto, V., Leleu, X., Morschhauser, F., Karlin, L., Broussais, F., Rezai, K., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00021-1 · Cited by 417
BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure
Anand, P., Brown, J. D., Lin, C. Y., Qi, J., Zhang, R., Artero, P. C., Alaiti, M. A., Bullard, J., Alazem, K., Margulies, K. B., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.013 · Cited by 406
You, J., Croyle, J. L., Nishimura, A., Ozato, K., & Howley, P. M. (2004) · Cell · doi:10.1016/s0092-8674(04)00402-7 · Cited by 402
Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription
Bisgrove, D. A., Mahmoudi, T., Henklein, P., & Verdin, E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705053104 · Cited by 387
Devaiah, B. N., Lewis, B. A., Cherman, N., Hewitt, M. C., Albrecht, B. K., Robey, P. G., Ozato, K., Sims, R. J., & Singer, D. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120422109 · Cited by 378
Selective Recognition of Acetylated Histones by Bromodomain Proteins Visualized in Living Cells
Kanno, T., Kanno, Y., Siegel, R. M., Jang, M. K., Lenardo, M. J., & Ozato, K. (2004) · Molecular Cell · doi:10.1016/s1097-2765(03)00482-9 · Cited by 361
BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin
Devaiah, B. N., Case-Borden, C., Gegonne, A., Hsu, C. H., Chen, Q., Meerzaman, D., Dey, A., Ozato, K., & Singer, D. S. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3228 · Cited by 361
Yang, Z., He, N., & Zhou, Q. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01020-07 · Cited by 347
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
Ciceri, P., Müller, S., O'Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. A., Pallares, G., Picaud, S., Wells, C., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1471 · Cited by 338
Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains
Chung, C.-W., Coste, H., White, J. H., Mirguet, O., Wilde, J., Gosmini, R. L., Delves, C., Magny, S. M., Woodward, R., Hughes, S. A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200108t · Cited by 334
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling
Floyd, S. R., Pacold, M. E., Huang, Q., Clarke, S. M., Lam, F. C., Cannell, I. G., Bryson, B. D., Rameseder, J., Lee, M. J., Blake, E. J., et al. (2013) · Nature · doi:10.1038/nature12147 · Cited by 329
Lockwood, W. W., Zejnullahu, K., Bradner, J. E., & Varmus, H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216363109 · Cited by 327
Mechanism and regulation of acetylated histone binding by the tandem PHD finger of DPF3b
Zeng, L., Zhang, Q., Li, S., Plotnikov, A. N., Walsh, M. J., & Zhou, M.-M. (2010) · Nature · doi:10.1038/nature09139 · Cited by 318
Brd4 Marks Select Genes on Mitotic Chromatin and Directs Postmitotic Transcription
Dey, A., Nishiyama, A., Karpova, T., McNally, J., & Ozato, K. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-05-0380 · Cited by 316
Mirguet, O., Gosmini, R., Toum, J., Clément, C. A., Barnathan, M., Brusq, J.-M., Mordaunt, J. E., Grimes, R. M., Crowe, M., Pineau, O., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401088k · Cited by 305
Jiang, Y. W., Veschambre, P., Erdjument-Bromage, H., Tempst, P., Conaway, J. W., Conaway, R. C., & Kornberg, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8538 · Cited by 305
Krugmann, S., Anderson, K. E., Ridley, S. H., Risso, N., McGregor, A., Coadwell, J., Davidson, K., Eguinoa, A., Ellson, C. D., Lipp, P., et al. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00434-3 · Cited by 302
A Bromodomain Protein, MCAP, Associates with Mitotic Chromosomes and Affects G2-to-M Transition
Dey, A., Ellenberg, J., Farina, A., Coleman, A. E., Maruyama, T., Sciortino, S., Lippincott-Schwartz, J., & Ozato, K. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.17.6537-6549.2000 · Cited by 301
Li, Z., Guo, J., Wu, Y., & Zhou, Q. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks976 · Cited by 301
Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites
Vidler, L. R., Brown, N., Knapp, S., & Hoelder, S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300346w · Cited by 278
BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
Coudé, M.-M., Braun, T., Berrou, J., Dupont, M., Bertrand, S., Masse, A., Raffoux, E., Itzykson, R., Delord, M., Riveiro, M. E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4131 · Cited by 274
Shang, E., Nickerson, H. D., Wen, D., Wang, X., & Wolgemuth, D. J. (2007) · Development · doi:10.1242/dev.004481 · Cited by 273
BET bromodomain inhibition as a novel strategy for reactivation of HIV-1
Banerjee, C., Archin, N., Michaels, D., Belkina, A. C., Denis, G. V., Bradner, J., Sebastiani, P., Margolis, D. M., & Montano, M. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0312165 · Cited by 256
Reactivation of Latent HIV-1 by Inhibition of BRD4
Zhu, J., Gaiha, G. D., John, S. P., Pertel, T., Chin, C. R., Gao, G., Qu, H., Walker, B. D., Elledge, S. J., & Brass, A. L. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.09.008 · Cited by 244
Lange, M., Kaynak, B., Forster, U. B., Tönjes, M., Fischer, J. J., Grimm, C., Schlesinger, J., Just, S., Dunkel, I., Krueger, T., et al. (2008) · Genes & Development · doi:10.1101/gad.471408 · Cited by 242
BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice
Korb, E., Herre, M., Zucker-Scharff, I., Darnell, R. B., & Allis, C. D. (2015) · Nature Neuroscience · doi:10.1038/nn.4095 · Cited by 241
BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
Segura, M. F., Fontanals-Cirera, B., Gaziel-Sovran, A., Guijarro, M. V., Hanniford, D., Zhang, G., González-Gomez, P., Morante, M., Jubierre, L., Zhang, W., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0122-t · Cited by 239
Lamonica, J. M., Deng, W., Kadauke, S., Campbell, A. E., Gamsjaeger, R., Wang, H., Cheng, Y., Billin, A. N., Hardison, R. C., Mackay, J. P., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102140108 · Cited by 238
Bulatov, E., & Ciulli, A. (2015) · Biochemical Journal · doi:10.1042/bj20141450 · Cited by 237
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism
Boehm, D., Calvanese, V., Dar, R. D., Xing, S., Schroeder, S., Martins, L., Aull, K., Li, P.-C., Planelles, V., Bradner, J. E., et al. (2013) · Cell Cycle · doi:10.4161/cc.23309 · Cited by 235
Bailey, D., Jahagirdar, R., Gordon, A., Hafiane, A., Campbell, S., Chatur, S., Wagner, G. S., Hansen, H. C., Chiacchia, F. S., Johansson, J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.035 · Cited by 234
Ember, S. W. J., Zhu, J.-Y., Olesen, S. H., Martin, M. P., Becker, A., Berndt, N., Georg, G. I., & Schönbrunn, E. (2014) · ACS Chemical Biology · doi:10.1021/cb500072z · Cited by 221
3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands
Hewings, D. S., Wang, M., Philpott, M., Fedorov, O., Uttarkar, S., Filippakopoulos, P., Picaud, S., Vuppusetty, C., Marsden, B., Knapp, S., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200640v · Cited by 216
Albrecht, B. K., Gehling, V. S., Hewitt, M. C., Vaswani, R. G., Côté, A., Leblanc, Y., Nasveschuk, C. G., Bellon, S., Bergeron, L., Campbell, R., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01882 · Cited by 212
BRD4 is a novel therapeutic target for liver fibrosis
Ding, N., Hah, N., Yu, R. T., Sherman, M. H., Benner, C., Leblanc, M., He, M., Liddle, C., Downes, M., & Evans, R. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522163112 · Cited by 211
Brd4 links chromatin targeting to HPV transcriptional silencing
Wu, S.-Y., Lee, A.-Y., Hou, S. Y., Kemper, J. K., Erdjument-Bromage, H., Tempst, P., & Chiang, C.-M. (2006) · Genes & Development · doi:10.1101/gad.1448206 · Cited by 210
Seal, J., Lamotte, Y., Donche, F., Bouillot, A., Mirguet, O., Gellibert, F., Nicodeme, E., Krysa, G., Kirilovsky, J., Beinke, S., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.02.041 · Cited by 209
Wyce, A., Ganji, G., Smitheman, K. N., Chung, C.-W., Korenchuk, S., Bai, Y., Barbash, O., Le, B., Craggs, P. D., McCabe, M. T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072967 · Cited by 206
Fish, P. V., Filippakopoulos, P., Bish, G., Brennan, P. E., Bunnage, M. E., Cook, A. S., Federov, O., Gerstenberger, B. S., Jones, H., Knapp, S., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3010515 · Cited by 198
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
Kurimchak, A. M., Shelton, C., Duncan, K. E., Johnson, K. J., Brown, J., O’Brien, S., Gabbasov, R., Fink, L. S., Li, Y., Lounsbury, N., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.091 · Cited by 198
Place your BETs: the therapeutic potential of bromodomains
Prinjha, R. K., Witherington, J., & Lee, K. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.12.002 · Cited by 197
Chung, C.-W., Dean, A. W., Woolven, J. M., & Bamborough, P. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201320w · Cited by 188
Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors
Romero, F. A., Taylor, A. M., Crawford, T. D., Tsui, V., Côté, A., & Magnuson, S. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01514 · Cited by 188
Ceribelli, M., Kelly, P. N., Shaffer, A. L., Wright, G. W., Xiao, W., Yang, Y., Mathews Griner, L. A., Guha, R., Shinn, P., Keller, J. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411701111 · Cited by 185
Gosmini, R., Nguyen, V. L., Toum, J., Simon, C., Brusq, J.-M. G., Krysa, G., Mirguet, O., Riou-Eymard, A. M., Boursier, E. V., Trottet, L., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5010539 · Cited by 182
Hewings, D. S., Rooney, T. P. C., Jennings, L. E., Hay, D. A., Schofield, C. J., Brennan, P. E., Knapp, S., & Conway, S. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300915b · Cited by 181
Jung, M., Philpott, M., Müller, S., Schulze, J., Badock, V., Eberspächer, U., Moosmayer, D., Bader, B., Schmees, N., Fernández‐Montalván, A. E., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.523019 · Cited by 178
Bamborough, P., Diallo, H., Goodacre, J. D., Gordon, L., Lewis, A., Seal, J. T., Wilson, D. M., Woodrow, M. D., & Chung, C.-W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201283q · Cited by 175
BET acetyl-lysine binding proteins control pathological cardiac hypertrophy
Spiltoir, J. I., Stratton, M. S., Cavasin, M. A., Demos-Davies, K., Reid, B. G., Qi, J., Bradner, J. E., & McKinsey, T. A. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.07.017 · Cited by 174
Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression
Gacias, M., Gerona‐Navarro, G., Plotnikov, A. N., Zhang, G., Zeng, L., Kaur, J., Moy, G. A., Rusinova, E. V., Rodríguez, Y., Matikainen, B., et al. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.05.009 · Cited by 171
da Motta, L. L., Ledaki, I., Purshouse, K. R., Haider, S. A., Bastiani, M. A. D., Baban, D., Morotti, M., Steers, G., Wigfield, S., Bridges, E., et al. (2016) · Oncogene · doi:10.1038/onc.2016.184 · Cited by 170
Baratta, M. G., Schinzel, A. C., Zwang, Y., Bandopadhayay, P., Bowman-Colin, C., Kutt, J., Curtis, J., Piao, H., Wong, L. C., Kung, A. L., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422165112 · Cited by 168
Buckley, D. L., & Crews, C. M. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307761 · Cited by 168
Qiu, J. (2006) · Nature · doi:10.1038/441143a · Cited by 166
Design and characterization of bivalent BET inhibitors
Tanaka, M., Roberts, J. M., Seo, H., Souza, A., Paulk, J., Scott, T. G., DeAngelo, S. L., Dhe‐Paganon, S., & Bradner, J. E. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2209 · Cited by 166
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Rhyasen, G. W., Hattersley, M. M., Yao, Y., Dulak, A., Wang, W., Petteruti, P., Dale, I. L., Boiko, S., Cheung, T., Zhang, J., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0141 · Cited by 162
Self-citationMartin, M. P., Olesen, S. H., Georg, G. I., & Schönbrunn, E. (2013) · ACS Chemical Biology · doi:10.1021/cb4003283 · Cited by 158
A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes
Baud, M. G. J., Lin-Shiao, E., Cardote, T. A. F., Tallant, C., Pschibul, A., Chan, K.-H., Zengerle, M., Garcia, J. R., Kwan, T. T.-L., Ferguson, F. M., et al. (2014) · Science · doi:10.1126/science.1249830 · Cited by 157
BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer
Yokoyama, Y., Zhu, H., Lee, J., Kossenkov, A. V., Wu, S. Y., Wickramasinghe, J. M., Yin, X., Palozola, K. C., Gardini, A., Showe, L. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0854 · Cited by 154
Chiang, C. (2009) · F1000 Biology Reports · doi:10.3410/b1-98 · Cited by 150
Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands
Hewings, D. S., Fedorov, O., Filippakopoulos, P., Martin, S., Picaud, S., Tumber, A., Wells, C. D., Olcina, M. M., Freeman, K. M., Gill, A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301588r · Cited by 148
Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains
Zhang, G., Plotnikov, A. N., Rusinova, E. V., Shen, T., Morohashi, K., Joshua, J., Zeng, L., Mujtaba, S., Ohlmeyer, M. H. J., & Zhou, M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401334s · Cited by 143
Filippakopoulos, P., Picaud, S., Fedorov, O., Keller, M., Wrobel, M. N., Morgenstern, O., Bracher, F., & Knapp, S. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.10.080 · Cited by 142
Discovery of Novel Small-Molecule Inhibitors of BRD4 Using Structure-Based Virtual Screening
Vidler, L. R., Filippakopoulos, P., Fedorov, O., Picaud, S., Martin, S., Tomsett, M., Woodward, H. L., Brown, N., Knapp, S., & Hoelder, S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4011302 · Cited by 139
Jang, J. E., Eom, J.-I., Jeung, H.-K., Cheong, J., Lee, J. Y., Kim, J. S., & Min, Y. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1903 · Cited by 138
Structures of the Dual Bromodomains of the P-TEFb-activating Protein Brd4 at Atomic Resolution
Vollmuth, F., Blankenfeldt, W., & Geyer, M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033712 · Cited by 137
Jahagirdar, R., Zhang, H., Azhar, S., Tobin, J., Attwell, S., Yu, R., Wu, J., McLure, K. G., Hansen, H. C., Wagner, G. S., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.008 · Cited by 134
Structural basis for recognition of H3K56-acetylated histone H3–H4 by the chaperone Rtt106
Su, D., Hu, Q., Li, Q., Thompson, J. R., Cui, G., Fazly, A., Davies, B. A., Botuyan, M. V., Zhang, Z., & Mer, G. (2012) · Nature · doi:10.1038/nature10861 · Cited by 128
Tang, X., Peng, R., Phillips, J. E., Deguzman, J., Ren, Y., Apparsundaram, S., Luo, Q., Bauer, C. M. T., Fuentes, M. E., DeMartino, J. A., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.04.020 · Cited by 128
Gamsjaeger, R., Webb, S. R., Lamonica, J. M., Billin, A. N., Blobel, G. A., & Mackay, J. P. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05413-11 · Cited by 128
BET bromodomain inhibitors: a patent review
Garnier, J., Sharp, P. P., & Burns, C. J. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.859244 · Cited by 127
The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains
Dittmann, A., Werner, T., Chung, C., Savitski, M. M., Savitski, M. F., Grandi, P., Hopf, C., Lindon, M. J., Neubauer, G., Prinjha, R. K., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400789e · Cited by 124
Evolutions in fragment-based drug design: the deconstruction–reconstruction approach
Chen, H., Zhou, X., Wang, A., Zheng, Y., Gao, Y., & Zhou, J. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.015 · Cited by 123
Self-citationZhao, L., Cao, D., Chen, T., Wang, Y.-Q., Miao, Z., Xu, Y., Chen, W., Wang, X., Li, Y., Du, Z., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301793a · Cited by 123
Jones, M. H., Numata, M., & Shimane, M. (1997) · Genomics · doi:10.1006/geno.1997.5000 · Cited by 120
4‐Acyl Pyrroles: Mimicking Acetylated Lysines in Histone Code Reading
Lucas, X., Wohlwend, D., Hügle, M. J., Schmidtkunz, K., Gerhardt, S., Schüle, R., Jung, M., Einsle, O., & Günther, S. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201307652 · Cited by 120
Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases
Padmanabhan, B., Mathur, S., Manjula, R., & Tripathi, S. K. (2016) · Journal of Biosciences · doi:10.1007/s12038-016-9600-6 · Cited by 119
Tian, B., Zhao, Y., Sun, H., Zhang, Y., Yang, J., & Brasier, A. R. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00224.2016 · Cited by 119
Self-citationFrom ApoA1 upregulation to BET family bromodomain inhibition: Discovery of I-BET151
Mirguet, O., Lamotte, Y., Donche, F., Toum, J., Gellibert, F. J., Bouillot, A., Gosmini, R. L., Nguyen, V.-L., Delannée, D., Seal, J. T., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.125 · Cited by 115
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors
Xu, R., Zhao, Y., Liu, L., Bai, L., Yang, C., Zhou, B. N., Meagher, J. L., Chinnaswamy, K., Stuckey, J. A., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00613 · Cited by 113
Brd4 Is Essential for IL-1β-Induced Inflammation in Human Airway Epithelial Cells
Khan, Y. M., Kirkham, P., Barnes, P. J., & Adcock, I. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095051 · Cited by 108
Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors
Gehling, V. S., Hewitt, M. C., Vaswani, R. G., Leblanc, Y., Côté, A., Nasveschuk, C. G., Taylor, A. M., Harmange, J.-C., Audia, J. E., Pardo, E., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4001485 · Cited by 107
The EBNA1 Protein of Epstein-Barr Virus Functionally Interacts with Brd4
Lin, A., Wang, S., Nguyen, T., Shire, K., & Frappier, L. (2008) · Journal of Virology · doi:10.1128/jvi.01680-08 · Cited by 103
BRD4 Structure–Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536
Chen, L., Yap, J. L., Yoshioka, M., Lanning, M. E., Fountain, R. N., Raje, M. R., Scheenstra, J. A., Strovel, J. W., & Fletcher, S. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00084 · Cited by 101
The Making of I-BET762, a BET Bromodomain Inhibitor Now in Clinical Development
Zhao, Y., Yang, C., & Wang, S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4014407 · Cited by 98
Biased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors
McKeown, M. R., Shaw, D. L., Fu, H., Liu, S., Xu, X., Marineau, J., Huang, Y., Zhang, X., Buckley, D. L., Kadam, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501120z · Cited by 96
Raux, B., Voitovich, Y. V., Derviaux, C., Lugari, A., Rebuffet, E., Milhas, S., Priet, S., Roux, T., Trinquet, E., Guillemot, J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01708 · Cited by 88
Xue, X., Zhang, Y., Liu, Z., Song, M., Xing, Y., Xiang, Q., Wang, Z., Tu, Z., Zhou, Y., Ding, K., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01511 · Cited by 87
Self-citationTang, X., Peng, R., Ren, Y., Apparsundaram, S., Deguzman, J., Bauer, C. M. T., Hoffman, A. F., Hamilton, S. M., Liang, Z., Zeng, H., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.081661 · Cited by 78
Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity
Sartor, G. C., Powell, S. K., Brothers, S. P., & Wahlestedt, C. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0826-15.2015 · Cited by 76
Zhou, M., Keven, H., Jung, K., Cho, W.-K., Klase, Z. A., Kashanchi, F., Pise-Masison, C. A., & Brady, J. N. (2008) · Journal of Virology · doi:10.1128/jvi.01316-08 · Cited by 73
Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking
Zhao, H., Gartenmann, L., Dong, J., Spiliotopoulos, D., & Caflisch, A. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.04.017 · Cited by 73
Regulation of Aurora B Expression by the Bromodomain Protein Brd4
You, J., Li, Q., Wu, C., Kim, J., Ottinger, M., & Howley, P. M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00299-09 · Cited by 73
Hay, D. A., Fedorov, O., Filippakopoulos, P., Martin, S., Philpott, M., Picaud, S., Hewings, D. S., Uttakar, S., Heightman, T. D., Conway, S. J., et al. (2012) · MedChemComm · doi:10.1039/c2md20189e · Cited by 72
Chemical Inducers of Targeted Protein Degradation
Raina, K., & Crews, C. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.078105 · Cited by 70
The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb
Lu, P., Qu, X., Shen, Y., Jiang, Z., Wang, P., Zeng, H., Ji, H., Deng, J., Yang, X., Li, X., et al. (2016) · Scientific Reports · doi:10.1038/srep24100 · Cited by 70
Self-citationGagnon, D., Joubert, S., Sénéchal, H., Fradet‐Turcotte, A., Torre, S., & Archambault, J. (2009) · Journal of Virology · doi:10.1128/jvi.02468-08 · Cited by 68
Zhang, Z., Hou, S., Chen, H., Ran, T., Jiang, F., Bian, Y., Zhang, D., Zhi, Y., Wang, L., Zhang, L., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.04.034 · Cited by 68
Self-citationGaldeano, C., & Ciulli, A. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0059 · Cited by 66
Muralidharan, S. V., Bhadury, J., Nilsson, L. M., Green, L. C., McLure, K. G., & Nilsson, J. A. (2016) · Oncogene · doi:10.1038/onc.2015.521 · Cited by 64
Allen, B. K., Mehta, S., Ember, S. W. J., Schönbrunn, E., Ayad, N. G., & Schürer, S. C. (2015) · Scientific Reports · doi:10.1038/srep16924 · Cited by 63
Praphakar, R. A., Munusamy, M. A., Sadasivuni, K. K., & Rajan, M. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.09.080 · Cited by 62
Synthesis and biological evaluation of phosphatidylinositol phosphate affinity probes
Conway, S. J., Gardiner, J., Grove, S. J. A., Johns, M. K., Lim, Z., Painter, G. F., Robinson, D. E. J. E., Schieber, C., Thuring, J. W., Wong, L. S. ‐., et al. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b913399b · Cited by 61
Jinhong, P., Dong, W., Chen, L., Zou, T., Qi, Y., & Liu, Y. (2006) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-006-9223-6 · Cited by 60
Hügle, M. J., Lucas, X., Weitzel, G., Ostrovskyi, D., Breit, B., Gerhardt, S., Einsle, O., Günther, S., & Wohlwend, D. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01267 · Cited by 58
Zhao, L., Wang, Y.-Q., Cao, D., Chen, T., Wang, Q., Li, Y., Xu, Y., Zhang, N., Wang, X., Chen, D., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501504k · Cited by 52
Bromodomain Proteins in HIV Infection
Boehm, D., Conrad, R., & Ott, M. (2013) · Viruses · doi:10.3390/v5061571 · Cited by 47
Shapiro, G. I., Dowlati, A., LoRusso, P. M., Eder, J. P., Anderson, A., Do, K. T., Kagey, M. H., Sirard, C. A., Bradner, J. E., & Landau, S. B. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-a49 · Cited by 47
BET inhibitors in cancer therapeutics: a patent review
Ghoshal, A., Yugandhar, D., & Srivastava, A. K. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1159299 · Cited by 44
Yu, L., Wang, Z., Zhang, Z., Ren, X., Lu, X., & Ding, K. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150302110135 · Cited by 34
Fukazawa, H., & Masumi, A. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00527 · Cited by 33
Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains
Taylor, A. M., Vaswani, R. G., Gehling, V. S., Hewitt, M. C., Leblanc, Y., Audia, J. E., Bellon, S. F., Cummings, R. T., Côté, A., Harmange, J.-C., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500411h · Cited by 33
Herait, P., Berthon, C., Thiéblemont, C., Raffoux, E., Magarotto, V., Stathis, A., Thomas, X., Leleu, X. P., Gomez‐Roca, C., Odore, E., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-ct231 · Cited by 32
Evaluation of functional groups as acetyl-lysine mimetics for BET bromodomain inhibition
Sharp, P. P., Garnier, J., Huang, D. C. S., & Burns, C. J. (2014) · MedChemComm · doi:10.1039/c4md00182f · Cited by 28
Development of methyl isoxazoleazepines as inhibitors of BET
Hewitt, M. C., Leblanc, Y., Gehling, V. S., Vaswani, R. G., Côté, A., Nasveschuk, C. G., Taylor, A. M., Harmange, J.-C., Audia, J. E., Pardo, E., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.03.045 · Cited by 24
Noguchi‐Yachide, T., Sakai, T., Hashimoto, Y., & Yamaguchi, T. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.022 · Cited by 21
Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors
Li, J., Wang, P., Zhou, B., Shi, J., Liu, J., Li, X., Fan, L., Zheng, Y., & Ouyang, L. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.057 · Cited by 16
Self-citationEndo, J., Hikawa, H., Hamada, M., Ishibuchi, S., Fujie, N., Sugiyama, N., Tanaka, M., Kobayashi, H., Sugahara, K., Oshita, K., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.084 · Cited by 14
Gjoksi, B., Ghayor, C., Bhattacharya, I., Zenobi‐Wong, M., & Weber, F. E. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0209-2 · Cited by 13
Cited by
Exploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
BET Proteins as Targets for Anticancer Treatment
Stathis, A., & Bertoni, F. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0605 · Cited by 463
Bromodomains: a new target class for drug development
Cochran, A. G., Conery, A. R., & Sims, R. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0030-7 · Cited by 412
Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics
Ali, I., Conrad, R. J., Verdin, E., & Ott, M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00181 · Cited by 366
Targeting Transcription Factors for Cancer Treatment
Lambert, M., Jambon, S., Depauw, S., & David-Cordonnier, M.-H. (2018) · Molecules · doi:10.3390/molecules23061479 · Cited by 352
Metadata
- Authors
- Liu, Z., Wang, P., Chen, H., Wold, E. A., Tian, B., Brasier, A. R., & Zhou, J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-03-02
- Volume
- 60
- Issue
- 11
- Pages
- 4533-4558
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2587935821
- Cited by
- 303
- References
- 160
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.